向TREX1诱导药物耐药小细胞肺癌的先天性免疫反应
Takahiko Murayama1,2, Navin R Mahadevan3,4, Catherine B Meador5
1Nuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Cancer research communications
|August 23, 2024
概括
在小细胞肺癌 (SCLC) 中准TREX1使得耐化疗瘤重新敏感. 抑制TREX1诱导免疫反应,为治疗耐化学性SCLC提供了一种新的策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 小细胞肺癌 (SCLC) 呈现出初始的化疗敏感性,随后是获得的耐药性.
- 耐化学性SCLC由于有效的治疗选择有限而构成重大临床挑战.
- 背后的SCLC化学抵抗的分子机制尚未完全理解.
研究的目的:
- 调查三种主要修复外核酶1 (TREX1) 在SCLC化学抵抗中的作用.
- 探索TREX1作为克服SCLC耐药性的潜在治疗标.
- 评估TREX1抑制对瘤免疫性和化疗敏感性的影响.
主要方法:
- 在耐化学性SCLC模型和患者样本中分析TREX1表达.
- 使用测序 (ATAC-seq) 和色素免疫沉测序 (ChIP-seq) 测定转化酶可访问的染色质,以评估TREX1基因调节.
- 测试TREX1枯竭的研究,以评估对DNA传感途径和化疗敏感性的影响.
- 对STING通路激活和双链DNA积累的评估.
主要成果:
- 在耐化学性SCLC中,TREX1的表达显著上调.
- 在耐药细胞中观察到TREX1基因位点的增强色素可访问性和转录活性.
- TREX1的枯竭激活了cGAS-STING通路,导致细胞质中双链DNA的积累.
- 抑制TREX1增强了SCLC细胞的免疫性,并重新敏感化了耐化疗的细胞.
结论:
- 提升TREX1的调节有助于SCLC的化学抵抗和细胞存活.
- 向TREX1可以诱导先天性免疫反应,并使SCLC对化疗重新敏感.
- 抑制TREX1代表了耐化学性SCLC的有希望的治疗策略,特别是对于"免疫学"冷瘤.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
16.9K
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
02:53Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K